Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLSH | ISIN: JE00BJJN4441 | Ticker-Symbol: 16A
Tradegate
04.11.24
12:17 Uhr
6,100 Euro
+0,150
+2,52 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLARIVATE PLC Chart 1 Jahr
5-Tage-Chart
CLARIVATE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8506,00004.11.
PR Newswire
767 Leser
Artikel bewerten:
(2)

Clarivate Plc: New Webinar: Clarivate in the Age of AI - Empowering Our Life Sciences & Healthcare Customers to Create a Healthier Tomorrow

--- Henry Levy, President, Life Sciences & Healthcare, Provides a Virtual Update on Strategy and Generative AI Initiatives ---

LONDON, March 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the second video in a series of Clarivate in the Age of AI webinar presentations led by the Presidents of its three segments: Academia & Government, Intellectual Property and Life Sciences & Healthcare.


The Life Sciences & Healthcare video presentation highlights how Clarivate serves as an indispensable partner to our customers by providing solutions that enable mission critical decision making across the enterprise and the drug and medical device lifecycle. Henry Levy, President, Life Sciences & Healthcare, discusses how Clarivate is well-positioned in the market, our organic growth expansion strategy, and our strategy to leverage Generative AI across our solutions. The presentation concludes with two of our product leaders sharing demos of our recent Generative AI innovations.

"Our Life Sciences and Healthcare customers are some of the most innovative and data-intensive companies in the world, requiring increasingly sophisticated intelligence, analytics and expertise to put life-changing therapies into the hands of patients," said Levy. "We are focusing our investments into core platforms and new proprietary content that will empower us to penetrate new market opportunities and capture value faster across this ecosystem. We are applying emerging technologies like Generative AI to catalyze a transformation in our solution capabilities and drive expansion of our subscription revenue base."

The Life Sciences & Healthcare video webinar as well as the previously released Academia & Government webinar can be accessed at https://clarivate.com/AI/investor-webinar.

Clarivate plans to launch a webinar for the Intellectual Property segment the week of March 18, 2024.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Cautionary Note Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "likely," "may," "might," "plan," "potential," "predict," "project," "see," "seek," "should," "strategy," "strive," "target," "will," and "would" and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives; our belief that we have sufficient liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, inflation, foreign currency fluctuations, international hostilities, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption "Risk Factors" in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission ("SEC"). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.

Category: Webcast
Source: Clarivate Plc

Logo - https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/new-webinar-clarivate-in-the-age-of-ai---empowering-our-life-sciences--healthcare-customers-to-create-a-healthier-tomorrow-302087620.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.